KRAS Inhibitor Reduces Progression Risk in Pretreated Lung Cancer

By News Health
5 hours Ago

(MedPage Today) — Treatment with adagrasib (Krazati) significantly improved progression-free-survival (PFS) in previously treated patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC) compared with docetaxel, the phase III KRYSTAL…

Source link : https://www.medpagetoday.com/hematologyoncology/lungcancer/116919

Author :

Publish date : 2025-08-08 20:14:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

CDC Buildings Hit by Gunfire

Oddly viscous stars could be impersonating black holes

Trump Order Gives Political Appointees Review of Scientific Grants

Brain Autopsies Suggest MIND Diet Reduces Pathology

FDA Restricts Gene Therapy Skysona Due to Blood Cancer Risk

FDA Approves Zongertinib for HER2-Mutated NSCLC